Skip to content

Observational Study of Vamorolone in Children with Duchenne Muscular Dystrophy

Observational Study of Vamorolone in Children with Duchenne Muscular Dystrophy

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600123519
Enrollment
Unknown
Registered
2026-04-27
Start date
2026-05-01
Completion date
Unknown
Last updated
2026-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Duchenne/Becker muscular dystrophy

Interventions

Vamorolone Treatment Group:None
Prednisone Treatment Group:None

Sponsors

West China Second Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
4 Years to 18 Years

Inclusion criteria

Inclusion criteria: Only participants who meet **all** of the following criteria will be enrolled in this study: 1. Male participants aged 4 to 18 years; 2. Confirmed diagnosis of Duchenne muscular dystrophy (DMD) by genetic testing, with a defined genetic variant; 3. Vamorolone treatment group: participants with a regular history of prednisone use, who have switched to or plan to switch to vamorolone treatment, and who agree to comply with the required follow-up schedule; 4. Prednisone control group: participants with no prior vamorolone exposure, who have received regular prednisone treatment for >=6 months, and who agree to comply with the required follow-up schedule; 5. Written informed consent obtained from the legal guardian(s) of the participant.

Exclusion criteria

Exclusion criteria: Participants meeting **any** of the following criteria will be excluded from this study: 1. Presence of other inherited muscular diseases or neurological disorders (e.g., spinal muscular atrophy, cerebral palsy, etc.); 2. Severe failure of major organs including the heart, liver, kidney, or lung; 3. Presence of other serious conditions such as malignant tumors, severe infections, or coagulation disorders; 4. History of allergy to vamorolone, prednisone, or other study-related test reagents; 5. Current participation in other clinical trials; 6. Inability of the legal guardian to comply with follow-up requirements or refusal to provide written informed consent.

Design outcomes

Primary

MeasureTime frame
North Star Ambulatory Assessment, NSAA;Timing Function Test;

Secondary

MeasureTime frame
Serum creatine kinase;Height Z-score;Weight Z-score;BMI Z-score;Bone mineral density;bone turnover biomarkers;bone turnover biomarkers;

Countries

China

Contacts

Public ContactXiaotang Cai

West China Second University Hospital, Sichuan University

cxt_1999@126.com+86 181 8060 9237

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 7, 2026